These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30753642)

  • 1. Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial.
    Marrazzo JM; Rabe L; Kelly C; Richardson B; Deal C; Schwartz JL; Chirenje ZM; Piper J; Morrow RA; Hendrix CW; Marzinke MA; Hillier SL;
    J Infect Dis; 2019 May; 219(12):1940-1947. PubMed ID: 30753642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.
    Seay K; Khajoueinejad N; Zheng JH; Kiser P; Ochsenbauer C; Kappes JC; Herold B; Goldstein H
    J Virol; 2015 Sep; 89(18):9559-70. PubMed ID: 26157126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial.
    Bender Ignacio RA; Perti T; Magaret AS; Rajagopal S; Stevens CE; Huang ML; Selke S; Johnston C; Marrazzo J; Wald A
    J Infect Dis; 2015 Dec; 212(12):1949-56. PubMed ID: 26044291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
    Abdool Karim SS; Abdool Karim Q; Kharsany AB; Baxter C; Grobler AC; Werner L; Kashuba A; Mansoor LE; Samsunder N; Mindel A; Gengiah TN;
    N Engl J Med; 2015 Aug; 373(6):530-9. PubMed ID: 26244306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study.
    Celum C; Hong T; Cent A; Donnell D; Morrow R; Baeten JM; Firnhaber C; Grinsztejn B; Hosseinipour MC; Lalloo U; Nyirenda M; Riviere C; Sanchez J; Santos B; Supparatpinyo K; Hakim J; Kumarasamy N; Campbell TB;
    J Infect Dis; 2017 Mar; 215(6):907-910. PubMed ID: 28453835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
    Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
    N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety.
    Nixon B; Jandl T; Teller RS; Taneva E; Wang Y; Nagaraja U; Kiser PF; Herold BC
    Antimicrob Agents Chemother; 2014; 58(2):1153-60. PubMed ID: 24323471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial.
    Celum C; Wald A; Hughes J; Sanchez J; Reid S; Delany-Moretlwe S; Cowan F; Casapia M; Ortiz A; Fuchs J; Buchbinder S; Koblin B; Zwerski S; Rose S; Wang J; Corey L;
    Lancet; 2008 Jun; 371(9630):2109-19. PubMed ID: 18572080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir.
    Bunge KE; Dezzutti CS; Hendrix CW; Marzinke MA; Spiegel HML; Moncla BJ; Schwartz JL; Meyn LA; Richardson-Harman N; Rohan LC; Hillier SL
    J Int AIDS Soc; 2018 Aug; 21(8):e25156. PubMed ID: 30101439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men.
    Marcus JL; Glidden DV; McMahan V; Lama JR; Mayer KH; Liu AY; Montoya-Herrera O; Casapia M; Hoagland B; Grant RM
    PLoS One; 2014; 9(3):e91513. PubMed ID: 24637511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women.
    Wald A; Langenberg AG; Link K; Izu AE; Ashley R; Warren T; Tyring S; Douglas JM; Corey L
    JAMA; 2001 Jun; 285(24):3100-6. PubMed ID: 11427138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection.
    Vibholm L; Reinert LS; Søgaard OS; Paludan SR; Østergaard L; Tolstrup M; Melchjorsen J
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1404-11. PubMed ID: 22867119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.
    Mujugira A; Magaret AS; Celum C; Baeten JM; Lingappa JR; Morrow RA; Fife KH; Delany-Moretlwe S; de Bruyn G; Bukusi EA; Karita E; Kapiga S; Corey L; Wald A;
    J Infect Dis; 2013 Nov; 208(9):1366-74. PubMed ID: 23901094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalent Herpes Simplex Virus-2 Increases the Risk of Incident Bacterial Vaginosis in Women from South Africa.
    Abbai NS; Nyirenda M; Naidoo S; Ramjee G
    AIDS Behav; 2018 Jul; 22(7):2172-2180. PubMed ID: 28956191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
    Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.
    Ngandu NK; Carlson JM; Chopera DR; Ndabambi N; Abdool Karim Q; Abdool Karim S; Williamson C
    J Acquir Immune Defic Syndr; 2017 Sep; 76(1):43-47. PubMed ID: 28797020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa.
    Delany S; Mlaba N; Clayton T; Akpomiemie G; Capovilla A; Legoff J; Belec L; Stevens W; Rees H; Mayaud P
    AIDS; 2009 Feb; 23(4):461-9. PubMed ID: 19155993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
    Moss JA; Malone AM; Smith TJ; Kennedy S; Kopin E; Nguyen C; Gilman J; Butkyavichene I; Vincent KL; Motamedi M; Friend DR; Clark MR; Baum MM
    Antimicrob Agents Chemother; 2012 Feb; 56(2):875-82. PubMed ID: 22123689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High risk of human immunodeficiency virus in men who have sex with men with herpes simplex virus type 2 in the EXPLORE study.
    Brown EL; Wald A; Hughes JP; Morrow RA; Krantz E; Mayer K; Buchbinder S; Koblin B; Celum C
    Am J Epidemiol; 2006 Oct; 164(8):733-41. PubMed ID: 16896053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.